Less is not more

Here's a helpful comment by Drs. Filho and Burstein.

The PHARE, HORG, and SOLD studies also failed to demonstrate non-inferiority. To date, only one of 5 trials of shorter vs longer durations of adjuvant trastuzumab – the PERSEPHONE study of 6 vs 12 months – has demonstrated non-inferiority for a shorter regimen. All the others showed a measurable 2-3% reduction in recurrence risk with the longer duration of trastuzumab therapy.

The conclusion is that, for Her-2 positive breast cancer, 12 months of trastuzumab is still better than a shorter duration of giving the said drug.

But based on the data in Short-HER2 and four other trials of treatment duration, we believe that 12 months of trastuzumab, including 3 months of concurrent administration with taxane-based chemotherapy, remains the standard of care and the optimal duration of therapy. Lesser durations of trastuzumab maintenance treatment appear associated with a greater risk of disease recurrence.

The article's final statement is well-worded.

One year is a long time, especially when getting treatment for breast cancer. But for most women with HER2 positive tumors, that looks like time well spent.

Comments

Popular posts from this blog

Afternoons at home

Life happened

Once upon an island